MX2023008955A - Compuesto inhibidor de tyk2 que contiene anillo biciclico. - Google Patents
Compuesto inhibidor de tyk2 que contiene anillo biciclico.Info
- Publication number
- MX2023008955A MX2023008955A MX2023008955A MX2023008955A MX2023008955A MX 2023008955 A MX2023008955 A MX 2023008955A MX 2023008955 A MX2023008955 A MX 2023008955A MX 2023008955 A MX2023008955 A MX 2023008955A MX 2023008955 A MX2023008955 A MX 2023008955A
- Authority
- MX
- Mexico
- Prior art keywords
- compound containing
- bicyclic ring
- inhibitor compound
- containing bicyclic
- tyk2 inhibitor
- Prior art date
Links
- 229940123371 Tyrosine kinase 2 inhibitor Drugs 0.000 title abstract 2
- 125000002619 bicyclic group Chemical group 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 abstract 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un compuesto inhibidor de TYK2 que contiene un anillo bicíclico y su uso en la preparación de un fármaco para tratar o prevenir enfermedades relacionadas con TYK2.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110165856 | 2021-02-06 | ||
CN202110935764 | 2021-08-16 | ||
CN202111063960 | 2021-09-10 | ||
CN202210056272 | 2022-01-18 | ||
PCT/CN2022/075145 WO2022166917A1 (zh) | 2021-02-06 | 2022-01-30 | 含联环的tyk2抑制剂化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023008955A true MX2023008955A (es) | 2023-09-29 |
Family
ID=82740880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023008955A MX2023008955A (es) | 2021-02-06 | 2022-01-30 | Compuesto inhibidor de tyk2 que contiene anillo biciclico. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240182446A1 (es) |
EP (1) | EP4289833A1 (es) |
JP (1) | JP2024505912A (es) |
KR (1) | KR20230143611A (es) |
CN (1) | CN116783178A (es) |
AU (1) | AU2022216727A1 (es) |
CA (1) | CA3209830A1 (es) |
IL (1) | IL304766A (es) |
MX (1) | MX2023008955A (es) |
TW (1) | TW202233600A (es) |
WO (1) | WO2022166917A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023076161A1 (en) | 2021-10-25 | 2023-05-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI605041B (zh) * | 2012-11-08 | 2017-11-11 | 必治妥美雅史谷比公司 | 作爲IL-12、IL-23及/或IFNα反應之調節劑之經醯胺基取代雜環化合物 |
TWI582077B (zh) * | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲IL-12、IL-23及/或IFNα反應調節劑之經烷基-醯胺取代之吡啶化合物 |
AU2019373203A1 (en) * | 2018-10-30 | 2021-06-10 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha |
CN115715287A (zh) * | 2020-04-28 | 2023-02-24 | 百时美施贵宝公司 | 作为IL-12、IL-23和/或IFNα调节剂的经取代的N-(甲基-d3)哒嗪-3-甲酰胺或N-(甲基-d3)-烟酰胺化合物 |
-
2022
- 2022-01-27 TW TW111103735A patent/TW202233600A/zh unknown
- 2022-01-30 MX MX2023008955A patent/MX2023008955A/es unknown
- 2022-01-30 JP JP2023545921A patent/JP2024505912A/ja active Pending
- 2022-01-30 EP EP22749196.6A patent/EP4289833A1/en active Pending
- 2022-01-30 WO PCT/CN2022/075145 patent/WO2022166917A1/zh active Application Filing
- 2022-01-30 KR KR1020237029154A patent/KR20230143611A/ko unknown
- 2022-01-30 CN CN202280012962.1A patent/CN116783178A/zh active Pending
- 2022-01-30 AU AU2022216727A patent/AU2022216727A1/en active Pending
- 2022-01-30 CA CA3209830A patent/CA3209830A1/en active Pending
- 2022-01-30 US US18/263,293 patent/US20240182446A1/en active Pending
-
2023
- 2023-07-26 IL IL304766A patent/IL304766A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2022216727A1 (en) | 2023-09-07 |
WO2022166917A1 (zh) | 2022-08-11 |
TW202233600A (zh) | 2022-09-01 |
EP4289833A1 (en) | 2023-12-13 |
US20240182446A1 (en) | 2024-06-06 |
CA3209830A1 (en) | 2022-08-11 |
JP2024505912A (ja) | 2024-02-08 |
IL304766A (en) | 2023-09-01 |
KR20230143611A (ko) | 2023-10-12 |
CN116783178A (zh) | 2023-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501744A1 (en) | Methods for the administration of certain vmat2 inhibitors | |
MX2022005994A (es) | Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras. | |
MX2020007625A (es) | Inhibidor mtor, composicion farmaceutica y su uso. | |
HUP0400782A2 (hu) | Antikolinergikumokon és PDE-IV inhibitorokon alapuló új gyógyszerkészítmények | |
MX2022012285A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). | |
HK1075422A1 (en) | Use of il-18 inhibitors in the manufacture of medicaments | |
AU2018347307A1 (en) | Heterocyclic compounds and uses thereof | |
NZ616806A (en) | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor | |
SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
WO2018208793A8 (en) | S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY | |
MX2022005985A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
MX2021012418A (es) | Compuestos heterociclicos y sus usos. | |
MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
MX2023009685A (es) | Inhibidores de tyk2 y sus usos. | |
MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
JOP20220168A1 (ar) | طرق علاج الطحال | |
MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
MX2022010748A (es) | Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1). | |
MX2023008955A (es) | Compuesto inhibidor de tyk2 que contiene anillo biciclico. | |
MX2021013318A (es) | Terapias de combinacion que comprenden inhibidores de apremilast y tyk2. | |
MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
MX2023009723A (es) | Inhibidores de tyk2 y sus usos. | |
NZ751972A (en) | Treatment of prurigo nodularis | |
MX2022000811A (es) | Inhibidores de enzimas. | |
MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. |